{
  "metadata": {
    "title": "Comprehensive Evidence-Based Research on Bipolar Disorder",
    "description": "Authoritative research compilation from NHS, PubMed, WHO, CDC, NICE, EMA, and APA",
    "compiled_date": "2026-01-06",
    "compiled_by": "Senior Healthcare Scientist, UK",
    "version": "1.0",
    "language_coverage": ["UK English", "US English"],
    "primary_sources": [
      "NHS (National Health Service, UK)",
      "PubMed Database",
      "WHO (World Health Organization)",
      "CDC (Centers for Disease Control and Prevention, US)",
      "NICE (National Institute for Health and Care Excellence, UK)",
      "EMA (European Medicines Agency)",
      "APA (American Psychiatric Association)"
    ]
  },
  
  "diagnosis": {
    "overview": {
      "uk_terminology": "Bipolar disorder (formerly manic depression)",
      "us_terminology": "Bipolar disorder",
      "description": "A mental health condition characterized by extreme mood swings, including periods of high mood (mania or hypomania) and low mood (depression), affecting mood, energy, activity levels, and functional ability."
    },
    
    "diagnostic_criteria": {
      "dsm5": {
        "source": "American Psychiatric Association DSM-5",
        "general_principles": [
          "Symptoms must not be attributable to substance effects or another medical condition",
          "Episodes not better explained by schizoaffective disorder, schizophrenia, or delusional disorder",
          "Emphasis on changes in activity and energy alongside mood disturbances"
        ],
        "bipolar_i_disorder": {
          "criteria": "At least one manic episode (major depressive episode common but not required)",
          "manic_episode_definition": {
            "duration": "At least 7 consecutive days (or any duration if hospitalization necessary)",
            "core_features": "Abnormally and persistently elevated, expansive, or irritable mood AND abnormally increased activity or energy",
            "required_symptoms": "3 or more symptoms (4 if mood only irritable)",
            "symptoms": [
              "Inflated self-esteem or grandiosity",
              "Decreased need for sleep",
              "More talkative than usual or pressure to keep talking",
              "Flight of ideas or racing thoughts",
              "Distractibility",
              "Increase in goal-directed activity or psychomotor agitation",
              "Excessive involvement in activities with high potential for painful consequences"
            ],
            "severity": "Marked impairment in functioning, hospitalization necessary, or psychotic features present"
          }
        },
        "bipolar_ii_disorder": {
          "criteria": "At least one hypomanic episode AND at least one major depressive episode, with no history of full manic episode",
          "hypomanic_episode_definition": {
            "duration": "At least 4 consecutive days",
            "core_features": "Persistently elevated, expansive, or irritable mood AND increased activity or energy",
            "required_symptoms": "3 or more symptoms (4 if mood only irritable)",
            "symptoms": "Same as manic episode",
            "severity": "Unequivocal change in functioning observable by others, NOT severe enough to cause marked impairment or require hospitalization, no psychotic features"
          }
        },
        "cyclothymic_disorder": {
          "criteria": "Numerous periods of hypomanic symptoms (not meeting full criteria) and depressive symptoms (not meeting full criteria) for at least 2 years (1 year in children/adolescents)",
          "exclusions": "Criteria for major depressive, manic, or hypomanic episodes never met during this period"
        },
        "major_depressive_episode": {
          "duration": "2-week period",
          "required_symptoms": "5 or more symptoms, including depressed mood or loss of interest/pleasure",
          "symptoms": [
            "Depressed mood most of the day, nearly every day",
            "Markedly diminished interest or pleasure in activities",
            "Significant weight loss/gain or appetite changes",
            "Insomnia or hypersomnia",
            "Psychomotor agitation or retardation",
            "Fatigue or loss of energy",
            "Feelings of worthlessness or excessive guilt",
            "Decreased ability to think or concentrate",
            "Recurrent thoughts of death or suicidal ideation"
          ],
          "impairment": "Clinically significant distress or impairment in functioning"
        },
        "specifiers": [
          "With rapid cycling (4+ mood episodes in 12 months)",
          "With psychotic features (mood-congruent or mood-incongruent)",
          "With mixed features",
          "With anxious distress",
          "With catatonia",
          "With peripartum onset",
          "With seasonal pattern"
        ]
      },
      
      "icd11": {
        "source": "WHO ICD-11 (effective January 2022)",
        "nomenclature": "Bipolar disorders (updated from 'bipolar affective disorders' in ICD-10)",
        "organizational_structure": "Grouped under 'Bipolar or Related Disorders', with 'Mood Disorders' as superordinate grouping",
        "building_blocks_approach": "Mood episodes (depressive, manic, mixed, hypomanic) described first; longitudinal pattern determines diagnosis",
        "bipolar_i_disorder": "At least one past or present manic or mixed episode (depressive episodes may occur but not obligatory)",
        "bipolar_ii_disorder": "At least one hypomanic episode and major depressive episode, no history of manic episodes",
        "manic_episode": {
          "core_criteria": "Extreme and persistent mood changes (euphoria, irritability, expansiveness, mood lability) AND abnormally increased activity or subjective experience of increased energy",
          "accessory_symptoms": "Several of the following: increased talkativeness, flight of ideas, increased self-esteem/grandiosity, decreased need for sleep, distractibility, impulsive/reckless behavior, increased goal-directed activity",
          "duration": "Most of the day, nearly every day for minimum 1 week (unless shortened by treatment/hospitalization)",
          "functional_impairment": "Significant impairment in all areas of functioning, potentially requiring intensive treatment or hospitalization, may include psychotic symptoms"
        },
        "hypomanic_episode": {
          "core_criteria": "Same as manic episode",
          "duration": "Several days (interpreted as 4+ consecutive days)",
          "functional_impairment": "Significant change in usual mood and behavior apparent to those who know the individual well, does NOT involve marked impairment or psychosis"
        },
        "mixed_episodes": "Retained in ICD-11 (several prominent manic and depressive symptoms occurring simultaneously or alternating rapidly for at least 2 weeks)",
        "cyclothymic_disorder": "2-year period with multiple hypomanic and dysthymic symptoms not reaching threshold for mania or formal depressive episode; symptoms can cause significant impairment",
        "key_differences_from_dsm5": [
          "ICD-11 retains mixed episodes as separate category",
          "ICD-11 maintains bereavement exclusion for depressive episodes",
          "ICD-11 retains dysthymic disorder as separate entity",
          "Less restrictive criteria for hypomanic functional impairment"
        ]
      }
    },
    
    "types_of_bipolar_disorder": {
      "bipolar_i": {
        "uk_description": "Characterised by at least one manic episode, which may be preceded or followed by hypomanic or major depressive episodes",
        "us_description": "Characterized by at least one manic episode, which may be preceded or followed by hypomanic or major depressive episodes",
        "severity": "Most severe form, with full manic episodes"
      },
      "bipolar_ii": {
        "description": "At least one hypomanic episode and one major depressive episode, without full manic episodes",
        "characteristics": "Hypomania less severe than mania, but depressive episodes can be equally severe"
      },
      "cyclothymic_disorder": {
        "uk_description": "Chronic fluctuating mood disturbance with numerous hypomanic and depressive symptoms that do not meet full criteria for episodes",
        "us_description": "Chronic fluctuating mood disturbance with numerous hypomanic and depressive symptoms that do not meet full criteria for episodes",
        "duration": "At least 2 years (1 year in children/adolescents)"
      },
      "rapid_cycling": {
        "definition": "Four or more distinct mood episodes within 12 months",
        "prevalence": "Occurs in 10-20% of bipolar disorder cases",
        "characteristics": "More common in women, associated with worse prognosis"
      },
      "mixed_episodes": {
        "uk_description": "Simultaneous or rapidly alternating manic and depressive symptoms",
        "us_description": "Simultaneous or rapidly alternating manic and depressive symptoms",
        "risk": "Increased risk of suicide",
        "dsm5_approach": "Uses 'with mixed features' specifier",
        "icd11_approach": "Retains as separate diagnostic category"
      }
    },
    
    "assessment_tools": {
      "screening_methods": [
        {
          "name": "Mood Disorder Questionnaire (MDQ)",
          "purpose": "Screening tool for bipolar disorder",
          "setting": "Primary care and research"
        },
        {
          "name": "Young Mania Rating Scale (YMRS)",
          "purpose": "Assess severity of manic symptoms",
          "setting": "Clinical assessment and research"
        },
        {
          "name": "Hamilton Depression Rating Scale (HDRS)",
          "purpose": "Assess severity of depressive symptoms",
          "setting": "Clinical assessment"
        },
        {
          "name": "Beck Depression Inventory (BDI)",
          "purpose": "Self-report measure of depression severity",
          "setting": "Clinical and research"
        },
        {
          "name": "Structured Clinical Interview for DSM (SCID)",
          "purpose": "Comprehensive diagnostic assessment",
          "setting": "Research and specialist clinical settings"
        },
        {
          "name": "MINI International Neuropsychiatric Interview",
          "purpose": "Brief structured diagnostic interview",
          "setting": "Clinical and research"
        }
      ],
      "clinical_assessment_components": [
        "Detailed psychiatric history including mood episodes",
        "Episodes of overactivity/disinhibition",
        "Symptoms between episodes",
        "Triggers and relapse patterns",
        "Family history of mood disorders",
        "Developmental and lifelong mood changes",
        "Social and personal functioning",
        "Psychosocial stressors",
        "Mental and physical comorbidities",
        "Medication history and treatment response",
        "Risk assessment (self-harm, suicide, harm to others)"
      ],
      "nice_recommendations": {
        "primary_care": "Inquire about previous periods of overactivity or disinhibited behaviour lasting 4+ days when adults present with depression",
        "specialist_assessment": "Full psychiatric assessment in service capable of offering comprehensive interventions",
        "questionnaire_use": "Should NOT be used in primary care to identify bipolar disorder"
      }
    },
    
    "differential_diagnosis": {
      "conditions_to_consider": [
        {
          "condition": "Major Depressive Disorder (Unipolar Depression)",
          "key_differences": "No history of manic or hypomanic episodes; bipolar disorder often misdiagnosed as MDD initially"
        },
        {
          "condition": "Schizophrenia Spectrum Disorders",
          "key_differences": "Psychotic symptoms persist beyond mood episodes in schizophrenia; negative symptoms more prominent"
        },
        {
          "condition": "Schizoaffective Disorder",
          "key_differences": "Psychotic symptoms occur in absence of mood episodes"
        },
        {
          "condition": "Personality Disorders (especially Borderline)",
          "key_differences": "Mood instability more reactive to interpersonal events; identity disturbance; chronic pattern"
        },
        {
          "condition": "Attention-Deficit/Hyperactivity Disorder (ADHD)",
          "key_differences": "Symptoms present since childhood; no distinct mood episodes; different quality of symptoms"
        },
        {
          "condition": "Substance Use Disorders",
          "key_differences": "Mood symptoms directly related to substance use/withdrawal; temporal relationship crucial"
        },
        {
          "condition": "Medical Conditions",
          "examples": "Hyperthyroidism, hypothyroidism, Cushing's syndrome, multiple sclerosis, brain tumours",
          "key_differences": "Physical examination and laboratory tests reveal underlying medical cause"
        }
      ],
      "misdiagnosis_statistics": {
        "prevalence": "Up to 76.8% of individuals with bipolar disorder experience misdiagnosis",
        "common_misdiagnoses": ["Major depressive disorder", "Schizophrenia", "Borderline personality disorder"],
        "diagnostic_delay": "Average 5-10 years from symptom onset to correct diagnosis",
        "racial_disparities": "African-American men 25% more likely to be misdiagnosed with schizophrenia vs 7% for Caucasian men"
      }
    }
  },
  
  "treatment_options": {
    "overview": {
      "general_principles": [
        "Bipolar disorder cannot be cured but can be effectively managed",
        "Treatment combines pharmacological and psychosocial interventions",
        "Individualised treatment plans essential",
        "Lifelong management typically required",
        "Shared decision-making with patients and carers"
      ],
      "treatment_goals": [
        "Stabilise mood and prevent episodes",
        "Reduce severity and frequency of episodes",
        "Improve functioning and quality of life",
        "Prevent relapse",
        "Reduce suicide risk",
        "Manage comorbid conditions"
      ]
    },
    
    "pharmacological_interventions": {
      "mood_stabilisers": {
        "uk_spelling": "mood stabilisers",
        "us_spelling": "mood stabilizers",
        "overview": "Cornerstone of bipolar disorder treatment for acute episodes and long-term maintenance",
        "medications": [
          {
            "name": "Lithium",
            "indications": [
              "Acute mania/hypomania",
              "Bipolar depression",
              "Long-term relapse prevention (especially manic episodes)",
              "Suicide prevention"
            ],
            "efficacy": "Gold standard with strongest evidence for long-term relapse prevention",
            "monitoring_requirements": [
              "Serum lithium levels (therapeutic range 0.6-1.2 mmol/L)",
              "Renal function (creatinine, eGFR)",
              "Thyroid function (TSH, T4)",
              "Calcium levels",
              "ECG in patients with cardiac risk factors"
            ],
            "monitoring_frequency": "Every 3-6 months once stable",
            "side_effects": [
              "Tremor",
              "Weight gain",
              "Polyuria and polydipsia",
              "Hypothyroidism",
              "Renal impairment",
              "Cognitive effects",
              "Nausea",
              "Diarrhoea"
            ],
            "contraindications": [
              "Severe renal impairment",
              "Addison's disease",
              "Untreated hypothyroidism"
            ],
            "pregnancy_considerations": "Avoid if possible, especially first trimester (risk of Ebstein's anomaly); if essential, use lowest effective dose with careful monitoring",
            "nice_guidance": "Should not be initiated in primary care except under shared-care arrangements",
            "ema_status": "Authorised for bipolar disorder treatment",
            "predictors_of_response": [
              "Family history of bipolar disorder and lithium response",
              "Preserved euthymic intervals",
              "Classical mania-depression-interval cycles"
            ]
          },
          {
            "name": "Valproate (Valproic acid, Divalproex sodium)",
            "uk_spelling": "Valproate",
            "us_spelling": "Valproate",
            "indications": [
              "Acute mania/hypomania",
              "Mixed episodes",
              "Maintenance treatment (especially for atypical forms, rapid cycling, dysphoric mania)"
            ],
            "efficacy": "Effective for acute mania and maintenance; particularly useful for rapid cycling and mixed states",
            "monitoring_requirements": [
              "Liver function tests",
              "Full blood count",
              "Serum valproate levels (therapeutic range 50-125 mg/L)"
            ],
            "side_effects": [
              "Weight gain",
              "Tremor",
              "Hair loss",
              "Hepatotoxicity",
              "Pancreatitis",
              "Thrombocytopenia",
              "Sedation"
            ],
            "critical_safety_warnings": {
              "mhra_ema_restrictions": [
                "Must NOT be initiated in individuals under 55 years unless two specialists independently agree no other effective/tolerated treatment exists",
                "Must NOT be used in women and girls of childbearing potential unless other options unsuitable AND Pregnancy Prevention Programme in place",
                "Boys and men must use effective contraception during treatment and for 3 months after stopping",
                "Men planning family within next year should discuss fertility risks with healthcare professional"
              ],
              "teratogenic_risks": [
                "11% risk of malformations in babies if taken during pregnancy",
                "30-40% risk of developmental disorders in children exposed in utero",
                "Includes neural tube defects, facial abnormalities, limb defects, cardiac malformations"
              ],
              "pregnancy_prevention_programme_requirements": [
                "Assessment of pregnancy potential",
                "Pregnancy tests before starting and regularly during treatment",
                "Counselling on risks",
                "Effective contraception (two forms recommended)",
                "Regular specialist reviews (at least annually)",
                "Risk acknowledgement form completion"
              ]
            },
            "nice_guidance": "Should not be initiated in primary care",
            "ema_authorisation": "Treatment of manic episode in bipolar disorder when lithium is contraindicated or not tolerated; continuation after manic episode may be considered in responders",
            "fda_approval": "Acute mania (divalproex); acute mania and mixed episodes (divalproex extended release)"
          },
          {
            "name": "Lamotrigine",
            "indications": [
              "Bipolar depression (less severe episodes)",
              "Long-term maintenance (especially for preventing depressive episodes)",
              "Bipolar II disorder"
            ],
            "efficacy": "Strong evidence for preventing depressive relapses; modest effect in acute bipolar depression",
            "titration": "Requires slow dose escalation over several weeks to reduce risk of serious rash",
            "side_effects": [
              "Rash (including Stevens-Johnson syndrome - rare but serious)",
              "Headache",
              "Nausea",
              "Dizziness",
              "Insomnia"
            ],
            "monitoring": "Clinical monitoring for rash, especially during titration",
            "pregnancy_considerations": "Relatively safer than valproate; folic acid supplementation recommended"
          },
          {
            "name": "Carbamazepine",
            "indications": [
              "Acute mania/hypomania",
              "Maintenance treatment (alternative when lithium ineffective)",
              "Rapid cycling and dysphoric mania"
            ],
            "efficacy": "Effective for acute mania; may be better than lithium for rapid cycling",
            "monitoring_requirements": [
              "Liver function tests",
              "Full blood count",
              "Serum carbamazepine levels"
            ],
            "side_effects": [
              "Dizziness",
              "Drowsiness",
              "Nausea",
              "Rash",
              "Hyponatraemia",
              "Leucopenia",
              "Hepatotoxicity"
            ],
            "drug_interactions": "Significant enzyme inducer - multiple drug interactions",
            "pregnancy_considerations": "Avoid if possible; risk of neural tube defects"
          }
        ]
      },
      
      "antipsychotics": {
        "overview": "Used for acute episodes and maintenance treatment; many have mood-stabilising properties",
        "first_generation_antipsychotics": {
          "examples": ["Haloperidol", "Chlorpromazine"],
          "use": "Primarily for acute mania; less commonly used long-term due to side effect profile",
          "side_effects": [
            "Extrapyramidal symptoms (EPS)",
            "Tardive dyskinesia",
            "Akathisia",
            "Parkinsonism"
          ]
        },
        "second_generation_atypical_antipsychotics": {
          "overview": "Broader therapeutic spectrum; fewer motor side effects than FGAs",
          "medications": [
            {
              "name": "Olanzapine",
              "indications": [
                "Acute mania/hypomania",
                "Bipolar depression (especially with fluoxetine combination)",
                "Maintenance treatment"
              ],
              "efficacy": "Highly effective for acute mania; FDA-approved for bipolar depression (with fluoxetine)",
              "side_effects": [
                "Significant weight gain",
                "Metabolic syndrome",
                "Diabetes risk",
                "Dyslipidaemia",
                "Sedation"
              ],
              "nice_recommendations": "First-line option for acute mania/hypomania",
              "ema_approval": "Approved for bipolar disorders",
              "monitoring": "Weight, BMI, glucose, lipids, blood pressure"
            },
            {
              "name": "Quetiapine",
              "indications": [
                "Acute mania",
                "Bipolar depression (monotherapy)",
                "Maintenance treatment"
              ],
              "efficacy": "Only medication specifically approved by EMA for bipolar depression in adults; effective across all phases",
              "side_effects": [
                "Sedation",
                "Weight gain",
                "Metabolic effects",
                "Hypotension",
                "Dry mouth"
              ],
              "benefits": "Can improve sleep quality and comorbid anxiety",
              "nice_recommendations": "First-line option for acute mania/hypomania and bipolar depression",
              "monitoring": "Weight, glucose, lipids, blood pressure"
            },
            {
              "name": "Risperidone",
              "indications": [
                "Acute mania/hypomania",
                "Maintenance treatment"
              ],
              "efficacy": "Effective for acute mania",
              "side_effects": [
                "Extrapyramidal symptoms (higher risk than other SGAs)",
                "Hyperprolactinaemia",
                "Weight gain",
                "Metabolic effects"
              ],
              "formulations": "Oral and long-acting injectable available",
              "nice_recommendations": "First-line option for acute mania/hypomania"
            },
            {
              "name": "Aripiprazole",
              "indications": [
                "Acute mania/hypomania (including adolescents aged 13+)",
                "Maintenance treatment",
                "Prevention of recurrence"
              ],
              "mechanism": "Partial dopamine D2 receptor agonist (third-generation antipsychotic)",
              "efficacy": "Effective for acute mania and maintenance; inconsistent results for bipolar depression",
              "side_effects": [
                "Akathisia",
                "Restlessness",
                "Insomnia",
                "Nausea",
                "Lower risk of weight gain and metabolic effects"
              ],
              "ema_approval": "Approved for moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13+",
              "nice_recommendations": "First-line option for acute mania/hypomania",
              "formulations": "Oral and long-acting injectable"
            },
            {
              "name": "Lurasidone",
              "indications": [
                "Bipolar depression (monotherapy or with lithium/valproate)",
                "Prevention of recurrence"
              ],
              "efficacy": "Effective for bipolar depression; may improve cognition",
              "side_effects": [
                "Akathisia",
                "Nausea",
                "Sedation",
                "Favourable rates of weight gain"
              ],
              "ema_approval": "Approved for bipolar depression",
              "fda_approval": "Approved for bipolar depression"
            },
            {
              "name": "Cariprazine",
              "indications": [
                "Acute mania",
                "Bipolar depression",
                "Maintenance treatment"
              ],
              "mechanism": "Partial dopamine D2/D3 receptor agonist (third-generation antipsychotic)",
              "efficacy": "Significant antidepressant effect on bipolar depression; effective for mania",
              "side_effects": [
                "Akathisia",
                "Extrapyramidal symptoms",
                "Restlessness",
                "Favourable rates of weight gain"
              ],
              "fda_approval": "Approved for manic and depressive episodes in bipolar disorder"
            },
            {
              "name": "Asenapine",
              "indications": [
                "Acute mania/hypomania",
                "Maintenance treatment"
              ],
              "efficacy": "Effective for acute mania and preventing recurrence",
              "administration": "Sublingual",
              "side_effects": [
                "Oral hypoaesthesia",
                "Dysgeusia",
                "Sedation",
                "Weight gain"
              ],
              "ema_approval": "Approved for bipolar disorders"
            },
            {
              "name": "Ziprasidone",
              "indications": [
                "Acute mania/mixed episodes"
              ],
              "efficacy": "Effective for acute mania; inconsistent results for bipolar depression",
              "side_effects": [
                "QTc prolongation (requires ECG monitoring)",
                "Akathisia",
                "Sedation",
                "Lower risk of weight gain"
              ]
            },
            {
              "name": "Paliperidone",
              "indications": [
                "Acute mania (doses >6mg)"
              ],
              "efficacy": "Effective for acute mania",
              "formulations": "Oral and long-acting injectable"
            },
            {
              "name": "Lumateperone",
              "indications": [
                "Bipolar depression",
                "Prevention of recurrence"
              ],
              "mechanism": "Partial D3 and 5-HT1A agonist; serotonin transporter inhibitor",
              "fda_approval": "Approved for depressive episodes in bipolar I or II disorder"
            }
          ]
        },
        "general_considerations": [
          "Choice depends on episode type, previous response, side effect profile, patient preference",
          "Combination with mood stabilisers often used",
          "Regular monitoring for metabolic side effects essential",
          "Long-acting injectables available for some agents (improve adherence)"
        ]
      },
      
      "antidepressants": {
        "overview": "Controversial use in bipolar disorder due to risk of inducing mania",
        "indications": "Bipolar depression (only with mood stabiliser or antipsychotic)",
        "risks": [
          "Switching to mania/hypomania",
          "Rapid cycling",
          "Mood destabilisation"
        ],
        "recommendations": [
          "Should NOT be used as monotherapy",
          "Should NOT be used during manic/hypomanic episodes",
          "SSRIs preferred over tricyclics (lower switch risk)",
          "Combine with mood stabiliser or antipsychotic",
          "Use for shortest duration necessary",
          "Monitor closely for mood elevation"
        ],
        "evidence": "Meta-analyses show limited efficacy in bipolar depression; some studies show no difference from placebo",
        "nice_guidance": "Consider stopping antidepressant if person develops mania/hypomania while on antidepressant monotherapy"
      },
      
      "other_medications": {
        "benzodiazepines": {
          "examples": ["Lorazepam", "Clonazepam"],
          "indications": [
            "Short-term management of agitation",
            "Acute behavioural disturbance",
            "Insomnia",
            "Anxiety"
          ],
          "duration": "Short-term use only (risk of dependence)",
          "nice_guidance": "Can be considered for initial management of acute behavioural disturbance in addition to antimanic agent"
        }
      },
      
      "medication_management_principles": {
        "general_guidelines": [
          "Provide age-appropriate information on medication purpose, side effects, monitoring",
          "Collaborate with individual in medication choice",
          "Regularly review overall medication regimen",
          "Discuss impact of alcohol, tobacco, prescription/non-prescription, and illicit drugs",
          "Do not stop medication suddenly without medical guidance"
        ],
        "older_people": [
          "Use lower doses",
          "Consider increased risk of drug interactions",
          "Be aware of anticholinergic effects on cognitive function and mobility",
          "Ensure medical comorbidities are treated"
        ],
        "contraindicated_medications": [
          "Gabapentin (not recommended for bipolar disorder)",
          "Topiramate (not recommended for bipolar disorder)"
        ]
      }
    },
    
    "psychotherapy_approaches": {
      "overview": "Essential adjunct to pharmacotherapy; improves outcomes, adherence, and relapse prevention",
      "general_principles": [
        "Should be specifically developed for bipolar disorder or adapted appropriately",
        "Delivered by trained and experienced therapists",
        "Typically 12-30 sessions",
        "Can be individual, group, or family-based",
        "Evidence-based manuals should guide delivery"
      ],
      
      "cognitive_behavioural_therapy": {
        "uk_abbreviation": "CBT",
        "us_abbreviation": "CBT",
        "description": "Structured psychological intervention helping individuals identify and change negative thought patterns and behaviours",
        "typical_duration": "Average 20 sessions, followed by enhancement sessions",
        "phases": [
          {
            "phase": "Assessment (1-2 sessions)",
            "components": [
              "Clarify diagnosis using SCID or MINI",
              "Assess symptom severity (BDI, YMRS)",
              "Create life chart to identify triggers and early signs",
              "Formulate biopsychosocial understanding"
            ]
          },
          {
            "phase": "Psychoeducation (1-2 sessions)",
            "components": [
              "Information about bipolar disorder nature, symptoms, etiology",
              "Explain interaction between environment, thoughts, emotions, physiology, behaviours",
              "Emphasise biological factors and medication importance"
            ]
          },
          {
            "phase": "Interventions (20-25 sessions)",
            "components": [
              "Behavioural activation (for depression)",
              "Behavioural inhibition (for mania/hypomania)",
              "Cognitive restructuring",
              "Schema work",
              "Skill development (decision-making, assertiveness, problem-solving, social skills)"
            ]
          },
          {
            "phase": "Relapse/Recurrence Prevention (1-2 sessions)",
            "components": [
              "Medication compliance strategies",
              "Identifying early warning signs",
              "Creating functional coping plans",
              "Regulating daily rhythms",
              "Self-monitoring techniques"
            ]
          }
        ],
        "efficacy": {
          "relapse_reduction": "Pooled odds ratio 0.506 for reduced relapse rates",
          "depression_improvement": "Hedges's g of -0.494 for decreased depression",
          "mania_reduction": "Hedges's g of -0.581 for reduced mania severity",
          "functioning_improvement": "Hedges's g of 0.457 for increased psychosocial functioning",
          "time_considerations": "Most effective in first year; benefits may diminish beyond 18 months without booster sessions"
        },
        "nice_recommendations": "Second-line adjunctive treatment for acute depression and maintenance phase",
        "canmat_isbd_recommendations": "Second-line adjunctive treatment"
      },
      
      "family_focused_therapy": {
        "abbreviation": "FFT",
        "description": "Involves family members in psychoeducation, communication improvement, and problem-solving",
        "typical_duration": "At least 10 planned sessions over 3 months to 1 year",
        "components": [
          "Psychoeducation about bipolar disorder",
          "Communication enhancement training",
          "Problem-solving skills training",
          "Relapse prevention planning"
        ],
        "efficacy": [
          "Reduces relapse rates compared to individual psychoeducation",
          "Reduces hospitalisation rates",
          "Enhances family communication",
          "Improves medication adherence"
        ],
        "nice_recommendations": "Should be offered to individuals living with or in close contact with family; second-line adjunctive treatment for acute depression and maintenance",
        "canmat_isbd_recommendations": "Second-line adjunctive treatment"
      },
      
      "interpersonal_and_social_rhythm_therapy": {
        "abbreviation": "IPSRT",
        "description": "Focuses on stabilising daily routines and interpersonal relationships to regulate mood",
        "key_components": [
          "Establishing regular sleep-wake cycles",
          "Maintaining consistent daily routines (meals, work, exercise)",
          "Managing interpersonal relationships",
          "Addressing role transitions and disputes",
          "Medication adherence",
          "Managing stressful life events",
          "Reducing disruptions in social rhythms"
        ],
        "efficacy": [
          "Associated with delayed recurrences when social and circadian rhythms regulated",
          "Improves mood stability",
          "Enhances medication adherence"
        ],
        "nice_recommendations": "Can be offered as psychological intervention for bipolar disorder",
        "canmat_isbd_recommendations": "Third-line intervention in maintenance phase"
      },
      
      "psychoeducation": {
        "description": "Educates individuals and families about bipolar disorder, symptoms, triggers, and management strategies",
        "delivery_formats": [
          "Individual psychoeducation",
          "Group psychoeducation (often more effective)",
          "Family psychoeducation"
        ],
        "components": [
          "Information about bipolar disorder nature and course",
          "Medication adherence promotion",
          "Early detection of prodromal symptoms",
          "Lifestyle regularity encouragement",
          "Trigger identification",
          "Relapse prevention strategies"
        ],
        "efficacy": {
          "group_psychoeducation": [
            "Effective in preventing overall relapses (NNT 5-8)",
            "Effective in preventing manic/hypomanic relapses",
            "Not effective for preventing depressive relapses",
            "Improves medication adherence",
            "Improves short-term illness knowledge"
          ],
          "individual_psychoeducation": "May be less effective than group interventions"
        },
        "nice_recommendations": "Carer-focused education and support program should be offered early",
        "canmat_isbd_recommendations": "First-line adjunctive intervention for all patients"
      },
      
      "other_psychological_interventions": [
        {
          "name": "Interpersonal Therapy (IPT)",
          "description": "Focuses on relationships and their impact on mood",
          "nice_recommendations": "Can be offered as choice for bipolar depression"
        },
        {
          "name": "Behavioural Couples Therapy",
          "description": "Involves partner in treatment to improve relationship functioning and mood management",
          "nice_recommendations": "Can be offered as choice for bipolar depression"
        },
        {
          "name": "Peer Interventions",
          "description": "Support from individuals with lived experience of bipolar disorder",
          "canmat_isbd_recommendations": "Third-line intervention"
        },
        {
          "name": "Functional Remediation",
          "description": "Targets cognitive and functional impairments",
          "status": "Promising modality requiring further research"
        },
        {
          "name": "Mindfulness-Based Cognitive Therapy",
          "description": "Combines mindfulness practices with cognitive therapy",
          "status": "Promising modality; conflicting results as first-line treatment"
        },
        {
          "name": "Illness Management and Recovery",
          "description": "Structured program for self-management and recovery",
          "status": "Promising modality"
        }
      ]
    },
    
    "lifestyle_interventions": {
      "overview": "Modifiable lifestyle factors significantly impact bipolar disorder onset, trajectory, and outcomes",
      "six_pillars_of_lifestyle_psychiatry": [
        "Diet",
        "Physical activity",
        "Avoiding substance use",
        "Stress management",
        "Restorative sleep",
        "Social relationships"
      ],
      
      "specific_interventions": {
        "sleep_and_circadian_rhythm": {
          "importance": "Sleep disturbances prominent in bipolar disorder; can trigger mood episodes",
          "recommendations": [
            "Maintain regular sleep-wake schedule",
            "Aim for 7-9 hours sleep per night",
            "Avoid shift work if possible",
            "Limit caffeine intake, especially afternoon/evening",
            "Create conducive sleep environment (dark, quiet, cool)",
            "Avoid screens before bedtime"
          ],
          "interventions": [
            "Bright light exposure therapy",
            "Melatonin supplementation",
            "Interpersonal and social rhythm therapy",
            "Sleep hygiene education"
          ]
        },
        "physical_activity": {
          "benefits": [
            "Reduces depression and anxiety",
            "Promotes better sleep",
            "Improves overall physical health",
            "Enhances mood stability"
          ],
          "recommendations": [
            "Regular aerobic exercise (150 minutes moderate intensity per week)",
            "Anaerobic/resistance training",
            "Yoga and tai chi",
            "Avoid excessive exercise during manic episodes"
          ]
        },
        "diet_and_nutrition": {
          "recommendations": [
            "Balanced, healthy diet",
            "Mediterranean diet pattern",
            "Omega-3 fatty acids (may have mood-stabilising properties)",
            "Limit processed foods and sugar",
            "Maintain stable eating patterns",
            "Avoid excessive caffeine"
          ],
          "considerations": "Dietary interventions important for improving depressive symptoms and functioning"
        },
        "stress_management": {
          "importance": "Chronic stress can trigger manic or depressive episodes",
          "techniques": [
            "Mindfulness meditation",
            "Relaxation techniques (progressive muscle relaxation, deep breathing)",
            "Yoga",
            "Time management",
            "Problem-solving skills",
            "Setting realistic goals",
            "Avoiding overcommitment"
          ]
        },
        "substance_use_avoidance": {
          "substances_to_avoid": [
            "Recreational drugs (cannabis, cocaine, amphetamines)",
            "Excessive alcohol",
            "Smoking/tobacco"
          ],
          "reasons": [
            "Can trigger mood episodes",
            "Interfere with medication effectiveness",
            "Worsen symptoms",
            "Increase risk of rapid cycling",
            "Contribute to illness progression"
          ],
          "recommendations": "Aggressive screening and management of substance use disorders essential"
        },
        "social_relationships": {
          "importance": "Healthy social support crucial for mood stability",
          "recommendations": [
            "Maintain supportive relationships",
            "Communicate openly with family and friends",
            "Join support groups",
            "Avoid socially isolating",
            "Manage interpersonal conflicts constructively"
          ]
        },
        "routine_and_structure": {
          "recommendations": [
            "Maintain regular daily routines",
            "Consistent meal times",
            "Regular work/activity schedule",
            "Avoid frequent time zone changes",
            "Limit night flights if possible"
          ]
        }
      },
      
      "multidimensional_approach": "Research suggests multidimensional lifestyle interventions (addressing multiple domains) may have greater impact than single-domain interventions"
    },
    
    "emergency_crisis_treatment": {
      "overview": "Urgent intervention required for severe episodes or risk situations",
      
      "crisis_situations": [
        "Severe mania with psychotic features",
        "Severe depression with suicidal ideation",
        "Acute risk of self-harm or suicide",
        "Risk of harm to others",
        "Severe agitation or behavioural disturbance",
        "Inability to care for self",
        "Medical complications"
      ],
      
      "immediate_interventions": {
        "assessment": [
          "Urgent psychiatric assessment",
          "Risk assessment (suicide, self-harm, harm to others)",
          "Medical assessment (rule out organic causes)",
          "Collateral history from family/carers"
        ],
        "pharmacological": [
          {
            "indication": "Acute agitation/behavioural disturbance",
            "options": [
              "Intramuscular olanzapine",
              "Intramuscular aripiprazole",
              "Haloperidol (with caution due to EPS risk)",
              "Lorazepam (alone or with antipsychotic)"
            ]
          },
          {
            "indication": "Severe mania",
            "options": [
              "Antipsychotics (haloperidol, olanzapine, quetiapine, risperidone)",
              "Combination therapy (antipsychotic + mood stabiliser)",
              "Benzodiazepines for agitation"
            ]
          },
          {
            "indication": "Severe depression with suicidality",
            "options": [
              "Quetiapine",
              "Olanzapine-fluoxetine combination",
              "Electroconvulsive therapy (ECT) if medication ineffective or rapid response needed"
            ]
          }
        ],
        "non_pharmacological": [
          "Calming environment with reduced stimulation",
          "De-escalation techniques",
          "Safety planning",
          "Removal of means of self-harm",
          "Constant observation if high risk"
        ]
      },
      
      "hospitalisation": {
        "indications": [
          "Severe risk of self-harm or suicide",
          "Risk of harm to others",
          "Severe psychotic symptoms",
          "Inability to care for self",
          "Lack of adequate support at home",
          "Need for intensive monitoring",
          "Medical complications requiring inpatient care"
        ],
        "types": [
          "Voluntary admission",
          "Involuntary admission (under Mental Health Act in UK; varies by jurisdiction)"
        ]
      },
      
      "crisis_team_support": {
        "description": "Community-based intensive support as alternative to hospitalisation when appropriate",
        "services": [
          "Daily visits",
          "Medication management",
          "Risk monitoring",
          "Support for family/carers",
          "Liaison with other services"
        ]
      },
      
      "electroconvulsive_therapy": {
        "abbreviation": "ECT",
        "indications": [
          "Severe depression not responding to medication",
          "Severe mania not responding to medication",
          "Rapid symptom control needed to prevent harm",
          "Catatonia",
          "Patient preference (previous good response)"
        ],
        "efficacy": "Highly effective for severe episodes; rapid onset of action",
        "procedure": "Brief electrical stimulation of brain under general anaesthesia",
        "side_effects": [
          "Short-term memory impairment",
          "Confusion immediately post-treatment",
          "Headache",
          "Muscle aches"
        ],
        "nice_recommendations": "Second-line treatment for acute mania; consider for severe depression",
        "considerations": "Better tolerated in elderly; may be considered earlier in this population"
      },
      
      "other_brain_stimulation_therapies": [
        {
          "name": "Repetitive Transcranial Magnetic Stimulation (rTMS)",
          "indications": "Bipolar depression not responding to antidepressants",
          "status": "Being studied; low risk of memory/thinking effects",
          "nice_recommendations": "Third-line treatment for acute mania"
        },
        {
          "name": "Light Therapy",
          "indications": "Seasonal pattern bipolar depression",
          "efficacy": "Effective for seasonal affective disorder; may help bipolar depression with seasonal worsening"
        },
        {
          "name": "Ketamine",
          "indications": "Treatment-resistant bipolar depression",
          "status": "Under investigation; shows potential for short-term relief of depressive and suicidal symptoms",
          "considerations": "More research needed for long-term use and guidelines"
        }
      ],
      
      "crisis_planning": {
        "components": [
          "Doctor's contact information",
          "Support group contacts",
          "Trusted friends and family contacts",
          "Information on other health problems, medications, allergies",
          "Insurance details and preferred treatment facilities",
          "Triggers for episodes",
          "Warning signs of impending episode",
          "Calming and reassuring phrases",
          "Actions others should take during crisis",
          "Preferences for emergency staff interaction",
          "Reasons for living and importance of recovery"
        ],
        "nice_recommendations": "Joint risk management plan should be developed with patient and carer, including triggers, early warning signs, coping strategies, medication adjustment protocols, and crisis contact information"
      },
      
      "uk_crisis_contacts": [
        "NHS 111 (urgent mental health helpline)",
        "Local mental health crisis team",
        "GP (during surgery hours)",
        "Samaritans: 116 123 (24/7 confidential support)",
        "999 (emergency services for immediate danger)"
      ],
      
      "us_crisis_contacts": [
        "988 Suicide & Crisis Lifeline (call or text 988)",
        "911 (emergency services)",
        "Crisis Text Line: Text HOME to 741741",
        "SAMHSA National Helpline: 1-800-662-4357"
      ]
    }
  },
  
  "management_strategies": {
    "daily_management": {
      "self_monitoring": {
        "importance": "Essential for recognising patterns, triggers, and early warning signs",
        "methods": [
          "Mood diary/journal",
          "Mood tracking apps",
          "Sleep logs",
          "Activity logs",
          "Medication tracking",
          "Symptom checklists"
        ],
        "what_to_track": [
          "Daily mood ratings",
          "Sleep duration and quality",
          "Energy levels",
          "Medication adherence",
          "Stressful events",
          "Substance use",
          "Physical symptoms",
          "Social interactions"
        ],
        "benefits": [
          "Identify patterns and triggers",
          "Recognise early warning signs",
          "Facilitate communication with healthcare providers",
          "Inform treatment decisions",
          "Increase self-awareness",
          "Empower self-management"
        ]
      },
      
      "medication_adherence": {
        "importance": "Critical for preventing relapse and maintaining stability",
        "barriers": [
          "Side effects",
          "Feeling well (questioning need for medication)",
          "Missing the 'highs' of mania",
          "Complexity of regimen",
          "Cost",
          "Stigma",
          "Lack of insight during episodes"
        ],
        "strategies_to_improve_adherence": [
          "Education about importance of medication",
          "Simplify medication regimen when possible",
          "Use pill organisers or reminder apps",
          "Address side effects promptly",
          "Involve family/carers in medication management",
          "Regular review with healthcare provider",
          "Shared decision-making about treatment",
          "Long-acting injectable formulations (for some antipsychotics)"
        ]
      },
      
      "routine_and_structure": {
        "importance": "Helps stabilise circadian rhythms and mood",
        "recommendations": [
          "Maintain consistent sleep-wake schedule",
          "Regular meal times",
          "Structured daily activities",
          "Balance between activity and rest",
          "Avoid overcommitment",
          "Plan for transitions and changes"
        ]
      },
      
      "stress_management_techniques": [
        "Mindfulness meditation",
        "Deep breathing exercises",
        "Progressive muscle relaxation",
        "Yoga",
        "Tai chi",
        "Journaling",
        "Time in nature",
        "Creative activities (art, music)",
        "Problem-solving strategies",
        "Assertiveness training"
      ],
      
      "social_support": {
        "importance": "Strong social support associated with better outcomes",
        "strategies": [
          "Maintain connections with supportive family and friends",
          "Join support groups (in-person or online)",
          "Communicate openly about needs",
          "Educate loved ones about bipolar disorder",
          "Set boundaries when needed",
          "Seek peer support from others with lived experience"
        ]
      },
      
      "wellness_recovery_action_plan": {
        "abbreviation": "WRAP",
        "description": "Structured self-management tool for recognising triggers and relapse signs",
        "components": [
          "Wellness toolbox (strategies that help)",
          "Daily maintenance plan",
          "Triggers and action plans",
          "Early warning signs and action plans",
          "Crisis planning",
          "Post-crisis planning"
        ],
        "nice_recommendations": "Excellent tool for engaging individuals in self-management"
      }
    },
    
    "mood_tracking_and_monitoring": {
      "importance": "Enables early detection of mood changes and informed treatment decisions",
      
      "traditional_methods": [
        "Paper mood charts",
        "Life charts",
        "Mood diaries",
        "Symptom checklists"
      ],
      
      "digital_tools": {
        "overview": "Smartphone apps and wearable devices offer convenient, real-time mood monitoring",
        "benefits": [
          "Ease of use and accessibility",
          "Real-time data collection",
          "Visualisation of mood patterns",
          "Reminders and prompts",
          "Data sharing with healthcare providers",
          "Integration with other health data"
        ],
        "challenges": [
          "Privacy and data security concerns",
          "Variable quality and evidence base",
          "User engagement and adherence",
          "Not all apps specifically designed for bipolar disorder"
        ],
        "examples": [
          {
            "name": "eMoods Bipolar Mood Tracker",
            "features": [
              "Track daily highs and lows",
              "Record symptoms, irritability, sleep",
              "Medication tracking",
              "Generate downloadable reports",
              "Safety plan for suicide prevention",
              "Data stored locally on device (privacy feature)"
            ],
            "target_audience": "Individuals with bipolar disorder, depression, PTSD, anxiety"
          },
          {
            "name": "Bipolar UK Mood Tracker",
            "features": [
              "Record daily mood, medications, emotions, sleep",
              "Mood scale",
              "Descriptive words for mood",
              "Review and export data",
              "Data stored privately on device"
            ],
            "cost": "Free to download"
          },
          {
            "name": "PolarUs",
            "features": [
              "Measure and monitor quality of life using evidence-backed scale",
              "Self-management strategies",
              "Community-based participatory research framework"
            ],
            "target_audience": "People with bipolar disorder"
          },
          {
            "name": "LiveWell",
            "features": [
              "Daily self-monitoring",
              "Personalised wellness plans"
            ]
          },
          {
            "name": "ORBIT (Online, Recovery-Oriented Bipolar Individualised Tool)",
            "features": [
              "Web-based self-management intervention",
              "Interactive tools",
              "Educational materials",
              "Moderated discussion forums",
              "Multimedia content"
            ]
          }
        ],
        "considerations": [
          "Clinicians should inquire about patients' app use",
          "Discuss potential benefits and limitations",
          "Ensure apps have clear privacy policies",
          "Prefer apps with evidence base and clinical input",
          "Regular review of consumer-facing apps needed"
        ]
      },
      
      "passive_sensing_and_digital_phenotyping": {
        "description": "Collecting data from smartphone sensors and wearables to infer mental states",
        "data_sources": [
          "Geolocation (GPS)",
          "Accelerometer (activity levels)",
          "Call and text logs (social interaction)",
          "Screen time",
          "Typing speed and patterns",
          "Voice analysis",
          "Sleep patterns (from wearables)",
          "Heart rate and physiological data"
        ],
        "potential_benefits": [
          "Early detection of mood changes",
          "Continuous, objective monitoring",
          "Reduced recall bias",
          "Personalised predictions"
        ],
        "challenges": [
          "Privacy and ethical concerns",
          "Data validity and standardisation",
          "User comfort with data sharing",
          "Need for external validation of predictive models"
        ],
        "examples": [
          "BiAffect (tracks keyboard dynamics)",
          "Apps using GPS for activity monitoring"
        ]
      }
    },
    
    "trigger_identification_and_avoidance": {
      "common_triggers": [
        {
          "trigger": "Sleep disruption",
          "examples": ["Insomnia", "Oversleeping", "Irregular sleep schedule", "Shift work", "Jet lag"],
          "management": "Maintain regular sleep-wake schedule; prioritise sleep hygiene; avoid shift work if possible"
        },
        {
          "trigger": "Stress",
          "examples": ["Work stress", "Relationship problems", "Financial difficulties", "Major life changes"],
          "management": "Stress management techniques; problem-solving; seek support; avoid overcommitment"
        },
        {
          "trigger": "Substance use",
          "examples": ["Alcohol", "Recreational drugs", "Excessive caffeine"],
          "management": "Avoid alcohol and recreational drugs; limit caffeine; seek treatment for substance use disorders"
        },
        {
          "trigger": "Medication non-adherence",
          "examples": ["Stopping medication", "Missing doses", "Changing doses without medical advice"],
          "management": "Maintain medication adherence; discuss concerns with healthcare provider before making changes"
        },
        {
          "trigger": "Seasonal changes",
          "examples": ["Reduced daylight in winter", "Increased daylight in summer"],
          "management": "Light therapy; maintain routine; monitor mood closely during seasonal transitions"
        },
        {
          "trigger": "Overactivity and overstimulation",
          "examples": ["Taking on too many projects", "Excessive social activity", "Lack of downtime"],
          "management": "Pace activities; schedule rest periods; set realistic goals; learn to say no"
        },
        {
          "trigger": "Interpersonal conflicts",
          "examples": ["Arguments", "Relationship breakdowns", "Family tensions"],
          "management": "Communication skills; conflict resolution; family therapy; set boundaries"
        },
        {
          "trigger": "Hormonal changes",
          "examples": ["Menstrual cycle", "Pregnancy", "Postpartum", "Menopause"],
          "management": "Monitor mood in relation to hormonal changes; discuss with healthcare provider; consider hormonal treatments if appropriate"
        }
      ],
      
      "strategies_for_trigger_management": [
        "Keep detailed mood diary to identify personal triggers",
        "Develop action plans for each identified trigger",
        "Communicate triggers to family/carers",
        "Modify environment to reduce exposure to triggers when possible",
        "Build coping skills for unavoidable triggers",
        "Regular review of triggers with healthcare provider"
      ]
    },
    
    "sleep_hygiene_and_routine_management": {
      "importance": "Sleep disturbances both symptom and trigger of mood episodes",
      
      "sleep_hygiene_recommendations": [
        "Maintain consistent sleep-wake schedule (even on weekends)",
        "Create conducive sleep environment (dark, quiet, cool, comfortable)",
        "Limit screen time 1-2 hours before bed",
        "Avoid caffeine after midday",
        "Avoid alcohol close to bedtime",
        "Avoid large meals close to bedtime",
        "Regular physical activity (but not close to bedtime)",
        "Relaxation routine before bed (reading, warm bath, meditation)",
        "Use bed only for sleep and intimacy (not work or TV)",
        "If unable to sleep after 20 minutes, get up and do relaxing activity"
      ],
      
      "monitoring_sleep": [
        "Track sleep duration and quality",
        "Note factors affecting sleep",
        "Recognise changes in sleep as early warning sign",
        "Use sleep tracking apps or wearables if helpful"
      ],
      
      "when_to_seek_help": [
        "Persistent insomnia (difficulty falling or staying asleep)",
        "Hypersomnia (excessive sleeping)",
        "Significant changes in sleep pattern",
        "Sleep disturbances affecting daytime functioning"
      ]
    },
    
    "relapse_prevention": {
      "importance": "Preventing relapse crucial for long-term stability and quality of life",
      
      "early_warning_signs": {
        "manic_hypomanic_episode": [
          "Decreased need for sleep",
          "Increased energy and activity",
          "Racing thoughts",
          "Increased talkativeness",
          "Irritability",
          "Impulsive behaviour",
          "Increased confidence",
          "Distractibility",
          "Increased spending or risky behaviour"
        ],
        "depressive_episode": [
          "Low mood or sadness",
          "Loss of interest in activities",
          "Fatigue or low energy",
          "Sleep changes (insomnia or hypersomnia)",
          "Appetite changes",
          "Difficulty concentrating",
          "Feelings of worthlessness or guilt",
          "Social withdrawal",
          "Thoughts of death or suicide"
        ]
      },
      
      "relapse_prevention_strategies": {
        "pharmacological": [
          "Maintain mood stabiliser or antipsychotic medication",
          "Regular medication reviews",
          "Prompt adjustment of medication if early warning signs",
          "Long-term maintenance treatment (lithium, valproate, lamotrigine, antipsychotics)"
        ],
        "psychological": [
          "Cognitive behavioural therapy (CBT)",
          "Family-focused therapy",
          "Interpersonal and social rhythm therapy",
          "Psychoeducation",
          "Regular therapy sessions or booster sessions"
        ],
        "self_management": [
          "Daily mood monitoring",
          "Maintain regular routines",
          "Prioritise sleep",
          "Manage stress",
          "Avoid triggers",
          "Maintain social support",
          "Wellness Recovery Action Plan (WRAP)"
        ],
        "early_intervention": [
          "Recognise early warning signs",
          "Implement action plan promptly",
          "Contact healthcare provider early",
          "Increase monitoring and support",
          "Medication adjustment if needed",
          "Increase therapy sessions temporarily"
        ]
      },
      
      "evidence_for_relapse_prevention": {
        "pharmacological": [
          "Lithium: Strong evidence for preventing all relapses, especially manic",
          "Valproate: Effective for preventing all relapses and depressive relapses",
          "Lamotrigine: Strong evidence for preventing all relapses and depressive relapses",
          "Olanzapine: Effective for preventing all relapses and manic relapses",
          "Quetiapine: Effective for preventing all relapses",
          "Aripiprazole: Effective for preventing manic relapses"
        ],
        "psychological": [
          "CBT: Effective in first year; may need booster sessions for sustained effect",
          "Group psychoeducation: Effective for preventing overall and manic/hypomanic relapses (NNT 5-8)",
          "Family-focused therapy: May be beneficial",
          "Enhanced relapse prevention training for CMHT workers: Increases median time to next episode by ~8.5 weeks"
        ]
      },
      
      "nice_recommendations": [
        "Develop joint risk management plan with patient and carer",
        "Include identifiable triggers, early warning signs, coping strategies",
        "Protocols for medication adjustments",
        "Agreements between primary and secondary care for responding to increased risk",
        "Contact information for crisis situations"
      ]
    }
  },
  
  "support_resources": {
    "for_affected_persons": {
      "all_ages": {
        "self_management_strategies": [
          "Education about bipolar disorder",
          "Mood tracking and monitoring",
          "Medication adherence",
          "Recognising early warning signs",
          "Developing coping strategies",
          "Maintaining regular routines",
          "Stress management techniques",
          "Building support network"
        ],
        "coping_strategies": [
          "Mindfulness and meditation",
          "Relaxation techniques",
          "Physical exercise",
          "Creative outlets (art, music, writing)",
          "Journaling",
          "Problem-solving skills",
          "Assertiveness training",
          "Time management"
        ],
        "peer_support": [
          {
            "organisation": "Bipolar UK",
            "services": [
              "Support groups (local and online)",
              "Forums and blogs",
              "Information resources",
              "Peer support network",
              "eCommunity online support"
            ],
            "website": "www.bipolaruk.org",
            "uk_specific": true
          },
          {
            "organisation": "Depression and Bipolar Support Alliance (DBSA)",
            "services": [
              "Support groups",
              "Online resources",
              "Wellness tools",
              "Peer support"
            ],
            "website": "www.dbsalliance.org",
            "us_specific": true
          },
          {
            "organisation": "Mind",
            "services": [
              "Information on bipolar disorder",
              "Local support groups",
              "Online support",
              "Helpline"
            ],
            "website": "www.mind.org.uk",
            "uk_specific": true
          },
          {
            "organisation": "Rethink Mental Illness",
            "services": [
              "Advice and information",
              "Support groups",
              "Advocacy services"
            ],
            "website": "www.rethink.org",
            "uk_specific": true
          },
          {
            "organisation": "National Alliance on Mental Illness (NAMI)",
            "services": [
              "Education programs",
              "Support groups",
              "Helpline",
              "Advocacy"
            ],
            "website": "www.nami.org",
            "us_specific": true
          }
        ],
        "online_resources": [
          "Bipolar UK website and eCommunity",
          "Mind website",
          "NHS mental health pages",
          "DBSA website (US)",
          "NAMI website (US)",
          "International Bipolar Foundation",
          "Mental Health America"
        ]
      },
      
      "children_and_adolescents": {
        "specific_considerations": [
          "Age-appropriate education about bipolar disorder",
          "School accommodations and support",
          "Family involvement in treatment",
          "Peer support groups for young people",
          "Transition planning to adult services"
        ],
        "resources": [
          "CAMHS (Child and Adolescent Mental Health Services) - UK",
          "Young Minds - UK",
          "The Mix (support for under 25s) - UK",
          "Childline - UK"
        ]
      },
      
      "adults": {
        "employment_support": [
          "Disclosure considerations",
          "Workplace accommodations",
          "Occupational health services",
          "Vocational rehabilitation",
          "Supported employment programs"
        ],
        "financial_support": [
          "Disability benefits (if eligible)",
          "Financial advice services",
          "Lasting power of attorney (for financial management during episodes)"
        ]
      },
      
      "older_adults": {
        "specific_considerations": [
          "Medication adjustments for age",
          "Management of comorbid physical conditions",
          "Cognitive assessment if concerns",
          "Social isolation prevention",
          "Carer support"
        ]
      }
    },
    
    "for_parents_and_family": {
      "supporting_loved_ones": [
        "Learn about bipolar disorder",
        "Recognise warning signs of episodes",
        "Encourage treatment adherence",
        "Provide emotional support without enabling",
        "Maintain boundaries",
        "Take care of own wellbeing",
        "Involve other family and friends with consent"
      ],
      
      "communication_strategies": [
        "Listen without judgement",
        "Validate feelings",
        "Avoid criticism or blame",
        "Use calm, clear communication",
        "Choose appropriate times for discussions (not during acute episodes)",
        "Express concerns constructively",
        "Encourage professional help"
      ],
      
      "crisis_planning": [
        "Develop crisis plan together when person is well",
        "Know warning signs",
        "Have emergency contacts readily available",
        "Understand when to seek urgent help",
        "Know person's preferences for crisis management",
        "Agree on code words for distress",
        "Plan for practical matters (childcare, work, finances)"
      ],
      
      "family_interventions": {
        "family_focused_therapy": "Evidence-based intervention involving family in treatment",
        "family_psychoeducation": "Education about bipolar disorder for family members",
        "nice_recommendations": "Family intervention should be offered, ideally involving person with bipolar disorder, for 3 months to 1 year, with at least 10 planned sessions"
      },
      
      "carer_support": {
        "nice_recommendations": [
          "Carers should receive written and verbal information on diagnosis, management, recovery, support available, roles of care teams, and crisis help",
          "Carer-focused education and support program should be offered early",
          "Information sharing between person and carers should be negotiated early",
          "Carers may be entitled to carer's assessment from social care services"
        ],
        "resources": [
          {
            "organisation": "Bipolar UK",
            "services": "Resources specifically for family, friends, and carers",
            "uk_specific": true
          },
          {
            "organisation": "Carers UK",
            "services": "Information and support for carers",
            "uk_specific": true
          },
          {
            "organisation": "Rethink Mental Illness",
            "services": "Carer support services",
            "uk_specific": true
          },
          {
            "organisation": "NAMI Family Support Group",
            "services": "Support groups for family members",
            "us_specific": true
          }
        ]
      },
      
      "self_care_for_carers": [
        "Prioritise own physical and mental health",
        "Take breaks and respite care",
        "Maintain own social connections",
        "Seek support from other carers",
        "Set realistic expectations",
        "Recognise own limits",
        "Access carer support services"
      ]
    },
    
    "for_teachers_and_educators": {
      "classroom_accommodations": [
        "Flexible deadlines during difficult periods",
        "Quiet space for breaks if needed",
        "Modified workload during episodes",
        "Extra time for assignments or exams",
        "Note-taking assistance",
        "Reduced sensory stimulation if needed",
        "Communication plan with parents/carers"
      ],
      
      "recognising_signs": {
        "manic_hypomanic_signs": [
          "Increased energy and activity",
          "Decreased need for sleep",
          "Rapid speech",
          "Difficulty concentrating",
          "Impulsive behaviour",
          "Irritability or aggression",
          "Overconfidence",
          "Inappropriate behaviour"
        ],
        "depressive_signs": [
          "Low mood or sadness",
          "Loss of interest in activities",
          "Fatigue or low energy",
          "Difficulty concentrating",
          "Social withdrawal",
          "Decline in academic performance",
          "Expressions of hopelessness",
          "Absence from school"
        ]
      },
      
      "supporting_students": [
        "Maintain consistent routines",
        "Provide clear expectations and structure",
        "Offer encouragement and positive reinforcement",
        "Be aware of triggers (stress, sleep deprivation)",
        "Communicate regularly with parents/carers and mental health professionals",
        "Ensure student has access to school counsellor or mental health support",
        "Educate other staff about student's needs (with consent)",
        "Have plan for managing crises at school"
      ],
      
      "resources_for_educators": [
        "School mental health policies and procedures",
        "Training on mental health awareness",
        "Consultation with educational psychologists",
        "Liaison with CAMHS (UK) or school mental health services",
        "Mental health charities' educational resources"
      ]
    },
    
    "for_healthcare_professionals_and_carers": {
      "best_practices": [
        "Comprehensive assessment including collateral history",
        "Collaborative care planning with patient and family",
        "Regular monitoring and review",
        "Integrated care across services",
        "Evidence-based treatment approaches",
        "Cultural sensitivity and individualised care",
        "Trauma-informed care",
        "Recovery-oriented approach"
      ],
      
      "care_coordination": [
        "Clear communication between primary and secondary care",
        "Care coordinator or key worker assigned",
        "Regular multidisciplinary team meetings",
        "Shared care protocols for medication management",
        "Crisis plans in place and accessible",
        "Smooth transitions between services (e.g., CAMHS to adult services)"
      ],
      
      "professional_resources": {
        "guidelines": [
          {
            "name": "NICE Guideline CG185",
            "title": "Bipolar disorder: assessment and management",
            "year": "2014 (updated 2025)",
            "organisation": "National Institute for Health and Care Excellence",
            "uk_specific": true
          },
          {
            "name": "CANMAT/ISBD Guidelines",
            "title": "Guidelines for the management of patients with bipolar disorder",
            "year": "2018 (updated 2023)",
            "organisation": "Canadian Network for Mood and Anxiety Treatments / International Society for Bipolar Disorders"
          },
          {
            "name": "APA Practice Guideline",
            "title": "Practice Guideline for the Treatment of Patients With Bipolar Disorder",
            "year": "2002",
            "organisation": "American Psychiatric Association",
            "us_specific": true
          },
          {
            "name": "BAP Guidelines",
            "title": "Evidence-based guidelines for treating bipolar disorder",
            "year": "2016",
            "organisation": "British Association for Psychopharmacology",
            "uk_specific": true
          },
          {
            "name": "WHO mhGAP Intervention Guide",
            "title": "Mental Health Gap Action Programme Intervention Guide",
            "organisation": "World Health Organization",
            "focus": "Non-specialised health settings, particularly LMICs"
          }
        ],
        "training": [
          "Family interventions for psychosis and bipolar disorder training (HEE - UK)",
          "Psychological therapy training specific to bipolar disorder",
          "Medication management and monitoring",
          "Risk assessment and management",
          "Crisis intervention"
        ],
        "professional_organisations": [
          "Royal College of Psychiatrists (UK)",
          "American Psychiatric Association (US)",
          "International Society for Bipolar Disorders",
          "British Association for Psychopharmacology (UK)",
          "Canadian Network for Mood and Anxiety Treatments"
        ]
      },
      
      "monitoring_and_follow_up": {
        "primary_care": [
          "Annual review minimum (more frequent if concerns)",
          "Medication review",
          "Physical health monitoring (weight, BMI, cardiovascular, metabolic, liver, renal, thyroid function)",
          "Mental health review",
          "Support adherence to care plans and crisis plans",
          "Referral to secondary care if needed"
        ],
        "secondary_care": [
          "Regular appointments with psychiatrist and/or care coordinator",
          "Medication monitoring (including blood levels for lithium, valproate)",
          "Psychological therapy sessions",
          "Risk assessment",
          "Care plan reviews",
          "Physical health monitoring",
          "Transition planning (e.g., back to primary care when stable)"
        ]
      },
      
      "addressing_comorbidities": [
        "Anxiety disorders (40-60% lifetime prevalence)",
        "Substance use disorders (33-45%)",
        "ADHD",
        "Personality disorders",
        "Physical health conditions (diabetes, cardiovascular disease, obesity, thyroid disorders)",
        "Integrated treatment approaches",
        "Screening and management as per relevant guidelines"
      ]
    }
  },
  
  "intervention_skills_and_tactics": {
    "early_warning_signs_recognition": {
      "importance": "Early recognition enables prompt intervention and may prevent full episode",
      
      "manic_hypomanic_warning_signs": [
        "Decreased need for sleep (feeling rested after few hours)",
        "Increased energy and restlessness",
        "Racing thoughts or mind feeling 'sped up'",
        "Increased talkativeness",
        "Increased goal-directed activity or starting multiple projects",
        "Increased irritability or impatience",
        "Increased confidence or grandiose ideas",
        "Impulsive decisions (spending, travel, commitments)",
        "Increased sociability or sexual interest",
        "Difficulty concentrating or being easily distracted"
      ],
      
      "depressive_warning_signs": [
        "Low mood or feeling sad",
        "Loss of interest in usual activities",
        "Fatigue or low energy",
        "Sleep changes (difficulty sleeping or sleeping too much)",
        "Appetite changes",
        "Difficulty concentrating or making decisions",
        "Feelings of worthlessness or excessive guilt",
        "Social withdrawal",
        "Slowed thinking or movement",
        "Thoughts of death or suicide"
      ],
      
      "individual_variation": "Warning signs can vary between individuals; important to identify personal patterns",
      
      "monitoring_strategies": [
        "Daily mood tracking",
        "Sleep monitoring",
        "Activity level monitoring",
        "Feedback from family/friends",
        "Regular check-ins with healthcare provider",
        "Use of mood tracking apps or wearables"
      ]
    },
    
    "crisis_intervention_protocols": {
      "assessment": {
        "immediate_priorities": [
          "Ensure safety of individual and others",
          "Assess level of risk (suicide, self-harm, harm to others)",
          "Assess severity of symptoms",
          "Assess capacity and insight",
          "Identify immediate needs"
        ],
        "information_gathering": [
          "Current symptoms and duration",
          "Recent stressors or triggers",
          "Medication adherence",
          "Substance use",
          "Previous episodes and what helped",
          "Support system available",
          "Collateral information from family/carers if possible"
        ]
      },
      
      "immediate_interventions": {
        "for_mania_hypomania": [
          "Reduce stimulation (calm, quiet environment)",
          "Set clear, simple boundaries",
          "Avoid arguing or confrontation",
          "Offer medication if prescribed for acute use",
          "Remove access to credit cards, car keys if impulsive behaviour risk",
          "Ensure adequate hydration and nutrition",
          "Contact mental health team or crisis services",
          "Consider hospitalisation if severe or high risk"
        ],
        "for_depression": [
          "Ensure safety (remove means of self-harm)",
          "Provide supportive presence",
          "Encourage expression of feelings",
          "Offer medication if prescribed",
          "Encourage basic self-care (eating, hygiene)",
          "Avoid leaving person alone if suicidal",
          "Contact mental health team or crisis services",
          "Consider hospitalisation if high suicide risk"
        ],
        "for_mixed_episodes": [
          "Recognise increased suicide risk",
          "Combine strategies for both mania and depression",
          "Prioritise safety",
          "Seek urgent professional help",
          "Close monitoring essential"
        ]
      },
      
      "when_to_seek_urgent_help": [
        "Suicidal thoughts or plans",
        "Self-harm behaviour",
        "Risk of harm to others",
        "Severe psychotic symptoms",
        "Severe agitation or aggression",
        "Inability to care for self",
        "Refusal of necessary treatment",
        "Rapid deterioration"
      ],
      
      "crisis_contacts": {
        "uk": [
          "NHS 111 (urgent mental health helpline)",
          "Local mental health crisis team",
          "GP (during surgery hours)",
          "Samaritans: 116 123",
          "999 (emergency services)"
        ],
        "us": [
          "988 Suicide & Crisis Lifeline",
          "911 (emergency services)",
          "Crisis Text Line: Text HOME to 741741",
          "SAMHSA National Helpline: 1-800-662-4357"
        ]
      }
    },
    
    "de_escalation_techniques": {
      "general_principles": [
        "Remain calm and composed",
        "Speak slowly and clearly",
        "Use non-threatening body language",
        "Maintain appropriate personal space",
        "Show respect and empathy",
        "Listen actively",
        "Avoid arguing or confrontation",
        "Offer choices when possible",
        "Be patient"
      ],
      
      "verbal_techniques": [
        "Use person's name",
        "Speak in calm, reassuring tone",
        "Use simple, clear language",
        "Acknowledge person's feelings",
        "Validate concerns without agreeing with delusional content",
        "Redirect conversation if needed",
        "Offer reassurance",
        "Set clear, reasonable limits",
        "Avoid threats or ultimatums"
      ],
      
      "non_verbal_techniques": [
        "Maintain open, relaxed posture",
        "Avoid sudden movements",
        "Respect personal space",
        "Use appropriate eye contact (not staring)",
        "Position yourself at angle rather than directly facing",
        "Ensure exit route available",
        "Remove potential weapons or dangerous objects from environment"
      ],
      
      "environmental_modifications": [
        "Reduce noise and stimulation",
        "Provide calm, quiet space",
        "Ensure adequate lighting",
        "Remove audience if possible",
        "Offer comfortable seating",
        "Provide water or refreshments if appropriate"
      ],
      
      "what_to_avoid": [
        "Arguing or debating",
        "Raising voice",
        "Making threats",
        "Touching without permission",
        "Crowding or cornering",
        "Dismissing concerns",
        "Making promises you can't keep",
        "Showing fear or anxiety",
        "Using sarcasm or humour inappropriately"
      ],
      
      "when_de_escalation_not_working": [
        "Call for additional support",
        "Consider medication if prescribed and appropriate",
        "May need to involve emergency services",
        "Prioritise safety of all involved",
        "Document incident"
      ]
    },
    
    "safety_planning": {
      "components": [
        "Warning signs of crisis",
        "Internal coping strategies (things person can do alone)",
        "People and social settings that provide distraction",
        "People to ask for help",
        "Professionals or agencies to contact during crisis",
        "Making environment safe (removing means of self-harm)",
        "Reasons for living"
      ],
      
      "development_process": [
        "Develop collaboratively with person when they are well",
        "Involve family/carers if person agrees",
        "Make it specific and personalised",
        "Write it down and keep copies accessible",
        "Review and update regularly",
        "Share with healthcare team"
      ],
      
      "nice_recommendations": "Joint risk management plan should be developed with patient and carer, including triggers, early warning signs, coping strategies, medication adjustment protocols, and crisis contact information"
    },
    
    "communication_strategies": {
      "general_principles": [
        "Choose appropriate time and place",
        "Ensure privacy",
        "Allow adequate time",
        "Minimise distractions",
        "Be prepared to listen",
        "Show empathy and respect"
      ],
      
      "during_different_mood_states": {
        "during_mania_hypomania": [
          "Keep communication brief and simple",
          "Avoid lengthy discussions or debates",
          "Set clear boundaries",
          "Redirect if conversation becomes tangential",
          "Avoid making important decisions",
          "Document agreements in writing"
        ],
        "during_depression": [
          "Be patient and allow time for responses",
          "Offer reassurance",
          "Avoid minimising feelings",
          "Encourage small steps",
          "Avoid pressuring for immediate decisions",
          "Check understanding"
        ],
        "during_stable_periods": [
          "Discuss treatment plans and preferences",
          "Develop crisis plans",
          "Address concerns about medication or treatment",
          "Plan for future (work, relationships, goals)",
          "Review what helps and what doesn't"
        ]
      },
      
      "with_family_and_carers": [
        "Respect confidentiality while sharing necessary information",
        "Negotiate information sharing early",
        "Provide education about bipolar disorder",
        "Acknowledge carer's role and challenges",
        "Involve in treatment planning when appropriate",
        "Provide information on support services"
      ],
      
      "cultural_considerations": [
        "Be aware of cultural beliefs about mental illness",
        "Respect cultural values and practices",
        "Use interpreters if language barrier",
        "Adapt communication style to cultural norms",
        "Involve family in culturally appropriate ways"
      ]
    }
  },
  
  "evidence_based_interactive_management_tools": {
    "overview": {
      "importance": "Digital tools and gamification can enhance engagement, self-management, and treatment outcomes",
      "challenges": [
        "Variable quality and evidence base of available apps",
        "Privacy and data security concerns",
        "User engagement and long-term adherence",
        "Need for apps specifically designed for bipolar disorder",
        "Translational lag from research to publicly available tools"
      ]
    },
    
    "gamification_approaches": {
      "definition": "Application of game design elements to non-game contexts to boost engagement and motivate behaviour change",
      
      "common_elements": [
        "Levels or progress feedback",
        "Points or scoring",
        "Rewards or prizes",
        "Badges or achievements",
        "Narrative or theme",
        "Personalization",
        "Customization",
        "Challenges or quests",
        "Leaderboards (with caution in mental health)",
        "Unlockable content"
      ],
      
      "evidence": {
        "general_mental_health": [
          "Can improve resilience",
          "Can reduce attrition",
          "Positive impact on psychological well-being",
          "May reduce depressive symptoms",
          "Effectiveness depends on quality and integration of elements"
        ],
        "bipolar_disorder_specific": [
          "Under-researched area",
          "Bipolar disorder among least commonly targeted domains for gamified interventions",
          "Potential for enhancing engagement in mood tracking and self-management",
          "Need for further research on effectiveness and safety"
        ]
      },
      
      "examples": [
        {
          "name": "eQuoo",
          "description": "Gamified mental health app with levels, progress feedback, points, narratives, personalization, mini-games, and badges",
          "target": "General mental health, resilience",
          "evidence": "Demonstrated increases in resilience and decreases in anxiety and depression in student population; higher retention than control groups"
        }
      ],
      
      "considerations_for_bipolar_disorder": [
        "Ensure game elements don't overstimulate during manic phases",
        "Balance challenge with achievability to avoid frustration during depressive phases",
        "Personalise to individual's current mood state",
        "Include educational content alongside gamification",
        "Ensure privacy and data security",
        "Involve individuals with lived experience in design"
      ]
    },
    
    "progress_tracking_systems": {
      "mood_tracking": {
        "features": [
          "Daily mood ratings (visual scales, numerical scales)",
          "Sleep tracking",
          "Energy level tracking",
          "Symptom checklists",
          "Medication tracking",
          "Trigger and event logging",
          "Notes or journaling"
        ],
        "visualisation": [
          "Mood charts and graphs",
          "Colour-coded calendars",
          "Trend analysis",
          "Pattern recognition",
          "Correlation displays (e.g., sleep vs mood)"
        ],
        "benefits": [
          "Increased self-awareness",
          "Early warning sign detection",
          "Facilitates communication with healthcare providers",
          "Informs treatment decisions",
          "Empowers self-management"
        ]
      },
      
      "quality_of_life_tracking": {
        "description": "Monitoring broader aspects of wellbeing beyond mood",
        "domains": [
          "Physical health",
          "Psychological wellbeing",
          "Social relationships",
          "Environmental factors",
          "Functioning in daily activities"
        ],
        "example": "PolarUs app uses evidence-backed quality of life scale specific to bipolar disorder"
      },
      
      "goal_tracking": {
        "features": [
          "Set personal wellness goals",
          "Track progress towards goals",
          "Break goals into manageable steps",
          "Celebrate achievements",
          "Adjust goals as needed"
        ],
        "example": "Life Goals app helps align coping strategies with personal goals"
      }
    },
    
    "reward_and_streak_systems": {
      "purpose": "Motivate consistent engagement and positive behaviours",
      
      "types": [
        {
          "type": "Streak counters",
          "description": "Track consecutive days of app use or healthy behaviours",
          "benefits": "Encourages consistency; provides sense of achievement",
          "considerations": "Avoid excessive pressure; allow for 'grace days' during difficult periods"
        },
        {
          "type": "Achievement badges",
          "description": "Unlock badges for reaching milestones",
          "examples": "7-day streak, 30-day streak, completing educational modules, consistent mood tracking",
          "benefits": "Provides positive reinforcement; visualises progress"
        },
        {
          "type": "Points systems",
          "description": "Earn points for completing activities",
          "uses": "Can be purely motivational or unlock content/features",
          "considerations": "Ensure points don't create unhealthy competition or pressure"
        },
        {
          "type": "Virtual rewards",
          "description": "Unlock content, themes, or features",
          "examples": "New mood tracking options, relaxation exercises, educational articles",
          "benefits": "Provides tangible reward; encourages exploration of app features"
        }
      ],
      
      "evidence": "Suggested by users as potential motivators for app engagement; limited research on effectiveness specifically for bipolar disorder",
      
      "cautions": [
        "Avoid creating pressure that could worsen symptoms",
        "Ensure rewards are meaningful and not trivialising",
        "Allow flexibility for difficult periods",
        "Focus on intrinsic motivation alongside extrinsic rewards"
      ]
    },
    
    "interactive_management_games": {
      "concept": "Games designed to teach skills or provide therapeutic benefit",
      
      "potential_applications": [
        "Cognitive training games (attention, memory, executive function)",
        "Emotion regulation games",
        "Social skills training games",
        "Stress management games (relaxation, mindfulness)",
        "Problem-solving games",
        "Psychoeducation games"
      ],
      
      "examples_from_general_mental_health": [
        "SPARX (for depression in adolescents) - fantasy game teaching CBT skills",
        "MindLight (for anxiety in children) - neurofeedback game",
        "Personal Investigator (for depression) - detective game with CBT elements"
      ],
      
      "bipolar_disorder_specific": "Limited examples; area requiring development and research",
      
      "design_considerations": [
        "Evidence-based therapeutic content",
        "Engaging and enjoyable gameplay",
        "Appropriate difficulty level",
        "Personalisation to individual needs",
        "Integration with broader treatment plan",
        "Monitoring and feedback mechanisms",
        "Safety features (e.g., crisis resources)"
      ]
    },
    
    "digital_health_tools_and_apps": {
      "categories": [
        {
          "category": "Mood tracking apps",
          "examples": ["eMoods", "Bipolar UK Mood Tracker", "Daylio", "Moodpath"],
          "features": "Daily mood logging, symptom tracking, medication tracking, data visualisation, export for healthcare providers"
        },
        {
          "category": "Self-management apps",
          "examples": ["PolarUs", "Life Goals", "LiveWell"],
          "features": "Quality of life monitoring, goal setting, coping strategies, psychoeducation, personalised wellness plans"
        },
        {
          "category": "Web-based platforms",
          "examples": ["ORBIT"],
          "features": "Comprehensive self-management interventions, interactive tools, educational materials, moderated forums, multimedia content"
        },
        {
          "category": "Digital phenotyping apps",
          "examples": ["BiAffect"],
          "features": "Passive data collection (keyboard dynamics, GPS, activity, sleep), early warning sign detection, personalised predictions"
        },
        {
          "category": "Meditation and mindfulness apps",
          "examples": ["Headspace", "Calm", "Insight Timer"],
          "features": "Guided meditations, breathing exercises, sleep stories, mindfulness training",
          "note": "General mental health apps; not bipolar-specific but may be helpful adjuncts"
        },
        {
          "category": "CBT-based apps",
          "examples": ["MoodGYM", "Sanvello"],
          "features": "CBT exercises, thought records, behavioural activation, relaxation techniques",
          "note": "General mental health apps; may need adaptation for bipolar disorder"
        }
      ],
      
      "evaluation_frameworks": [
        {
          "name": "MIND Framework",
          "purpose": "Assess mental health app quality, safety, and functionality",
          "domains": "Clinical foundation, user engagement, data privacy and security, interoperability"
        },
        {
          "name": "Mobile App Rating Scale (MARS)",
          "purpose": "Evaluate quality of mobile health apps",
          "domains": "Engagement, functionality, aesthetics, information quality"
        }
      ],
      
      "recommendations_for_users": [
        "Look for apps with evidence base or clinical input",
        "Check privacy policy and data security measures",
        "Prefer apps specifically designed for bipolar disorder when available",
        "Discuss app use with healthcare provider",
        "Be aware that apps are adjuncts, not replacements for professional treatment",
        "Monitor own response to app use (helpful vs stressful)"
      ],
      
      "recommendations_for_clinicians": [
        "Inquire about patients' app use",
        "Discuss potential benefits and limitations",
        "Recommend evidence-based apps when appropriate",
        "Review data from apps if patient wishes to share",
        "Stay informed about available digital tools",
        "Provide guidance on evaluating app quality"
      ]
    },
    
    "age_appropriate_interventions": {
      "children": {
        "age_range": "Under 12 years",
        "considerations": [
          "Diagnosis rare in this age group",
          "Symptoms may present differently",
          "Family involvement essential",
          "School-based interventions important"
        ],
        "digital_tools": [
          "Age-appropriate educational games",
          "Simple mood tracking with visual aids (emoji scales, colour coding)",
          "Parent-assisted digital tools",
          "Interactive psychoeducation"
        ]
      },
      
      "adolescents": {
        "age_range": "13-18 years",
        "considerations": [
          "Increased prevalence compared to children",
          "Peer influence significant",
          "Transition planning to adult services",
          "Technology-native generation"
        ],
        "digital_tools": [
          "Smartphone apps for mood tracking",
          "Social media-style interfaces",
          "Gamified interventions",
          "Peer support forums (moderated)",
          "Educational videos and interactive content",
          "Text-based crisis support"
        ],
        "medications": [
          "Aripiprazole approved by EMA for moderate to severe manic episodes in Bipolar I (age 13+)",
          "FDA-approved medications include olanzapine (13+), lithium (12+), quetiapine, risperidone, aripiprazole (10+)"
        ]
      },
      
      "adults": {
        "age_range": "18-64 years",
        "considerations": [
          "Peak prevalence",
          "Work and family responsibilities",
          "Varied technology literacy"
        ],
        "digital_tools": [
          "Full range of mood tracking and self-management apps",
          "Web-based platforms",
          "Digital phenotyping",
          "Telehealth options",
          "Online support groups",
          "Comprehensive psychoeducation resources"
        ]
      },
      
      "elderly": {
        "age_range": "65+ years",
        "considerations": [
          "Comorbid physical health conditions",
          "Medication interactions",
          "Cognitive changes",
          "May have lower technology literacy",
          "Social isolation risk"
        ],
        "digital_tools": [
          "Simple, user-friendly interfaces",
          "Large text and clear visuals",
          "Voice-activated options",
          "Telehealth for accessibility",
          "Family-assisted digital tools",
          "Focus on medication management and physical health monitoring"
        ],
        "medications": "Lower doses recommended; ECT may be considered earlier due to better tolerability"
      }
    }
  },
  
  "language_considerations": {
    "uk_english_terminology": {
      "spelling_differences": [
        {"uk": "Bipolar disorder", "us": "Bipolar disorder", "note": "Same spelling"},
        {"uk": "Stabilise", "us": "Stabilize"},
        {"uk": "Recognise", "us": "Recognize"},
        {"uk": "Behaviour", "us": "Behavior"},
        {"uk": "Colour", "us": "Color"},
        {"uk": "Favour", "us": "Favor"},
        {"uk": "Honour", "us": "Honor"},
        {"uk": "Neighbour", "us": "Neighbor"},
        {"uk": "Analyse", "us": "Analyze"},
        {"uk": "Paralyse", "us": "Paralyze"},
        {"uk": "Centre", "us": "Center"},
        {"uk": "Metre", "us": "Meter"},
        {"uk": "Litre", "us": "Liter"},
        {"uk": "Defence", "us": "Defense"},
        {"uk": "Licence (noun)", "us": "License"},
        {"uk": "Practise (verb)", "us": "Practice"}
      ],
      "medical_terms": [
        {"uk": "Paediatric", "us": "Pediatric"},
        {"uk": "Anaesthesia", "us": "Anesthesia"},
        {"uk": "Oestrogen", "us": "Estrogen"},
        {"uk": "Haemoglobin", "us": "Hemoglobin"},
        {"uk": "Leukaemia", "us": "Leukemia"}
      ],
      "service_terminology": [
        {"uk": "GP (General Practitioner)", "us": "Primary care physician"},
        {"uk": "A&E (Accident and Emergency)", "us": "ER (Emergency Room)"},
        {"uk": "CAMHS (Child and Adolescent Mental Health Services)", "us": "Child and adolescent psychiatry services"},
        {"uk": "NHS (National Health Service)", "us": "Healthcare system (varies)"},
        {"uk": "Mental Health Act", "us": "Mental health laws (vary by state)"},
        {"uk": "Care coordinator", "us": "Case manager"},
        {"uk": "Carer", "us": "Caregiver"}
      ]
    },
    
    "us_english_terminology": {
      "spelling_differences": "See UK English section for comparison",
      "service_terminology": [
        {"us": "Primary care physician", "uk": "GP"},
        {"us": "ER (Emergency Room)", "uk": "A&E"},
        {"us": "Psychiatrist", "uk": "Psychiatrist", "note": "Same"},
        {"us": "Therapist/Counselor", "uk": "Therapist/Counsellor"},
        {"us": "Case manager", "uk": "Care coordinator"},
        {"us": "Caregiver", "uk": "Carer"}
      ]
    },
    
    "regional_medical_terminology_differences": [
      {
        "term": "Manic depression",
        "status": "Outdated term for bipolar disorder; still recognised but not preferred",
        "regions": "Both UK and US"
      },
      {
        "term": "Bipolar affective disorder",
        "status": "ICD-10 term; updated to 'bipolar disorder' in ICD-11",
        "regions": "International"
      },
      {
        "term": "Sectioned",
        "uk_usage": "Informal term for involuntary admission under Mental Health Act",
        "us_equivalent": "Committed or involuntarily admitted"
      }
    ],
    
    "cultural_considerations": [
      "Mental health stigma varies across cultures",
      "Some cultures may have different conceptualisations of mental illness",
      "Family involvement in treatment may be more or less expected depending on culture",
      "Use of interpreters important for non-English speakers",
      "Culturally adapted interventions may be more effective"
    ]
  },
  
  "statistics_and_epidemiology": {
    "global_burden": {
      "prevalence": "Approximately 0.5% of global population (37 million people in 2021)",
      "breakdown": "34 million adults and 3.8 million adolescents aged 10-19",
      "trends": "Global incidence and prevalence showed consistent upward trend from 1990 to 2021",
      "age_standardised_rates": {
        "incidence": "31.35 per 100,000 (1990) to 32.12 per 100,000 (2021)",
        "prevalence": "490.1 per 100,000 (1990) to 489.8 per 100,000 (2019)"
      },
      "regional_variations": "Americas had highest YLD number and rate; Southern Latin America saw largest increase in incidence",
      "gender": "Females and adolescents bear greater burden; higher incidence and prevalence rates",
      "who_ranking": "Fifth leading cause of disease burden among mental disorders"
    },
    
    "united_states": {
      "prevalence": {
        "past_year": "2.8% of US adults (approximately 7.3 million)",
        "lifetime": "1.5-4.4% of US adults",
        "adolescents": "2.9% lifetime prevalence (ages 13-18)",
        "comparison": "US has highest lifetime rate (4.4%) among 11 nations studied"
      },
      "age_of_onset": {
        "median": "25 years",
        "highest_rates": "Ages 25-29 (0.7%)",
        "early_onset": "Up to one-third of children/adolescents with depression may have early-onset bipolar disorder"
      },
      "gender_distribution": {
        "past_year": "Males 2.9%, Females 2.8% (similar)",
        "characteristics": "Women more likely to experience rapid cycling and depressive episodes; men slightly more prone to manic episodes and younger age at first episode"
      },
      "racial_ethnic_differences": {
        "highest_rate": "Native American/Alaskan Natives (1.5%)",
        "lowest_rate": "Asians (0.2%)",
        "treatment_disparities": "Native Hawaiian/Other Pacific Islanders 49% less likely to receive medication; non-Hispanic Blacks 46% less likely compared to non-Hispanic Whites",
        "misdiagnosis": "African-American men 25% more likely to be misdiagnosed with schizophrenia vs 7% for Caucasian men"
      },
      "impairment": {
        "serious": "82.9% of adults with bipolar disorder",
        "moderate": "17.1%",
        "adolescents": "2.6% experienced severe impairment"
      },
      "economic_burden": {
        "annual_cost": "$219.1 billion",
        "direct_medical": "$55 billion (25%)",
        "indirect_costs": "$164 billion (72-80%, primarily lost productivity)",
        "lost_productivity_alone": "$145 billion"
      },
      "mortality": {
        "life_expectancy_reduction": "Average 9.2 years",
        "suicide_risk": "10-30 times higher than general population",
        "suicide_attempts": "25-60% will attempt suicide in lifetime",
        "suicide_deaths": "4-19% die by suicide",
        "contribution_to_suicides": "3-14% of all suicide deaths annually"
      },
      "treatment_gaps": {
        "untreated": "50% in any given year",
        "diagnostic_delay": "Average 10 years from symptom onset to correct diagnosis",
        "accurate_diagnosis_timeline": "Only 1 in 4 get accurate diagnosis in less than 3 years",
        "treatment_resistance": "20-30% of Bipolar I patients continue experiencing symptoms despite treatment"
      },
      "regional_variations": "Inpatient stays range from 33.2 per 100,000 (Washington) to 150.6 per 100,000 (Illinois)"
    },
    
    "united_kingdom": {
      "prevalence": "Estimated 1-2% of population",
      "service_provision": "NHS provides comprehensive mental health services including specialist bipolar disorder teams",
      "challenges": "Concerns about under-diagnosis, under-treatment, and high threshold for specialist referral"
    },
    
    "comorbidity": {
      "psychiatric": [
        "Anxiety disorders: 40-60% lifetime prevalence",
        "Substance use disorders: 33-45%",
        "ADHD: Significant comorbidity",
        "Personality disorders: Common"
      ],
      "physical_health": [
        "Cardiovascular disease",
        "Diabetes",
        "Obesity",
        "Thyroid disorders",
        "Migraine",
        "Asthma"
      ],
      "impact": "Comorbidities lead to lower use of medical care, reduced treatment adherence, higher risk of adverse outcomes, and reduced life expectancy (13 years shorter than general population)"
    },
    
    "misdiagnosis": {
      "prevalence": "Up to 76.8% experience misdiagnosis",
      "common_misdiagnoses": ["Major depressive disorder", "Schizophrenia", "Borderline personality disorder"],
      "diagnostic_delay": "Average 5-10 years from symptom onset to correct diagnosis",
      "consequences": "Delayed appropriate treatment, inappropriate treatments (e.g., antidepressants alone), worse outcomes"
    }
  },
  
  "references_and_citations": {
    "primary_sources": [
      {
        "organisation": "NHS (National Health Service, UK)",
        "key_resources": [
          "NHS Mental Health Conditions: Bipolar Disorder",
          "NHS Trust Bipolar Services (Birmingham and Solihull, Lancashire and South Cumbria, etc.)",
          "NHS Inform Scotland: Bipolar Disorder"
        ],
        "urls": [
          "https://www.nhs.uk/mental-health/conditions/bipolar-disorder/",
          "https://www.nhsinform.scot/illnesses-and-conditions/mental-health/bipolar-disorder/"
        ]
      },
      {
        "organisation": "PubMed/NCBI",
        "key_topics": [
          "DSM-5 and ICD-11 diagnostic criteria",
          "Evidence-based treatment guidelines",
          "Psychotherapy effectiveness (CBT, FFT, IPSRT)",
          "Pharmacological interventions",
          "Relapse prevention strategies"
        ],
        "database": "https://pubmed.ncbi.nlm.nih.gov/"
      },
      {
        "organisation": "WHO (World Health Organization)",
        "key_resources": [
          "ICD-11 Classification of Bipolar Disorders",
          "Mental Health Gap Action Programme (mhGAP) Intervention Guide",
          "Bipolar Disorder Fact Sheet",
          "Global Burden of Disease Data"
        ],
        "urls": [
          "https://www.who.int/news-room/fact-sheets/detail/bipolar-disorder",
          "https://www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action-programme"
        ]
      },
      {
        "organisation": "CDC (Centers for Disease Control and Prevention, US)",
        "key_resources": [
          "Mental Health Surveillance Data",
          "Bipolar Disorder Statistics",
          "Public Health Approaches to Mental Health"
        ],
        "urls": [
          "https://www.cdc.gov/nchs/fastats/mental-health.htm",
          "https://www.cdc.gov/mental-health/"
        ]
      },
      {
        "organisation": "NICE (National Institute for Health and Care Excellence, UK)",
        "key_resources": [
          "Clinical Guideline CG185: Bipolar disorder: assessment and management (2014, updated 2025)",
          "Quality Standards for Bipolar Disorder"
        ],
        "url": "https://www.nice.org.uk/guidance/cg185"
      },
      {
        "organisation": "EMA (European Medicines Agency)",
        "key_resources": [
          "Approved medications for bipolar disorder",
          "Valproate safety restrictions and Pregnancy Prevention Programme",
          "Antipsychotic authorisations",
          "Clinical development guidelines for bipolar disorder treatments"
        ],
        "url": "https://www.ema.europa.eu/"
      },
      {
        "organisation": "APA (American Psychiatric Association)",
        "key_resources": [
          "DSM-5 Diagnostic Criteria for Bipolar Disorder",
          "DSM-5-TR Updates",
          "Practice Guideline for the Treatment of Patients With Bipolar Disorder (2002)"
        ],
        "url": "https://www.psychiatry.org/"
      }
    ],
    
    "additional_guidelines": [
      {
        "name": "CANMAT/ISBD Guidelines",
        "full_title": "Canadian Network for Mood and Anxiety Treatments and International Society for Bipolar Disorders Guidelines for the Management of Patients with Bipolar Disorder",
        "year": "2018 (updated 2023)",
        "focus": "Comprehensive evidence-based recommendations for assessment and treatment across lifespan"
      },
      {
        "name": "BAP Guidelines",
        "full_title": "British Association for Psychopharmacology Evidence-Based Guidelines for Treating Bipolar Disorder",
        "year": "2016",
        "focus": "Pharmacological management, psychoeducation, and behaviour change"
      },
      {
        "name": "IPS Clinical Practice Guidelines",
        "full_title": "Indian Psychiatric Society Clinical Practice Guidelines for Management of Bipolar Disorder",
        "year": "2017",
        "focus": "Pharmacological and psychosocial interventions"
      }
    ],
    
    "key_research_areas": [
      "Diagnostic criteria harmonisation (DSM-5 vs ICD-11)",
      "Pharmacological efficacy and safety",
      "Psychotherapy effectiveness",
      "Digital health interventions",
      "Relapse prevention strategies",
      "Comorbidity management",
      "Lifestyle interventions",
      "Early intervention and prevention",
      "Biomarkers and predictive models",
      "Health disparities and access to care"
    ]
  }
}
